In this video, Robert Lustig, MD, discusses the evolving concept of re-irradiation of primary brain tumors by reviewing three relevant clinical studies and a recent experience at the Roberts Proton Therapy Center at Penn Medicine. Dr. Lustig describes the studies, which involved the retreatment of glioblastomas with bevacizumab in combination with conventional fractionated, stereotactic and hypofractionated radiotherapy, with a focus on respective survival and time to progression benefits. His discussion of proton therapy examines a single case involving the retreatment of a brainstem tumor with pencil beam scanning.
- Clinical Briefing: Enrolling Clinical Trials: Proton Beam Radiation for WHO Grade IIII Meningiomas and Hemangiopericytomas
- Clinical Study: An enrolling clinical trial at Penn Medicine is evaluating the application of proton radiotherapy to the treatment of meningiomas and brain cancers.
- Dr. Lustig’s Profile